Thomapyrin by Sanofi - classic pain tablets stay on German shelves
Published on 07/24/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The Thomapyrin tablets lie in a small white blister pack, foil glinting under the harsh pharmacy LED light as the pharmacist slides them across the counter. Thomapyrin by Sanofi is one of those pain medicines many German households keep within arm’s reach.
Combination pain relief explained
Thomapyrin is a fixed-dose combination of acetylsalicylic acid, paracetamol and caffeine designed to treat headaches and other moderate pain quickly. The brand focuses on tension headaches and migraine-like attacks where plain paracetamol or ibuprofen sometimes feel too slow.
On the official German product page, Sanofi describes Thomapyrin Classic as indicated for mild to moderate pain, while Thomapyrin Intensiv is positioned for stronger headache pain. Both rely on the same three active ingredients but in slightly different dosages to address varying pain intensity.
Sanofi S.A. and its pain portfolio
For retail investors, Thomapyrin is one piece of Sanofi’s broader consumer health and pain relief business that complements its prescription drugs and vaccines.
How Thomapyrin works in practice
On Sanofi’s German consumer site, the company explains that acetylsalicylic acid and paracetamol act as analgesics, while caffeine enhances their pain-relieving effect and helps the medicine work faster. Clinical data cited by the brand show improved headache relief compared with single-substance tablets.
The recommended adult dosage for Thomapyrin Classic in Germany is one to two tablets, up to three times per day, with a maximum of six tablets in 24 hours. Thomapyrin Intensiv, which contains higher doses of the active substances, is taken less frequently and is usually reserved for stronger headaches.
Packaging, dosage forms and everyday use
Thomapyrin is sold in blister-packed film-coated tablets, typically in pack sizes of 10, 20 or 50 tablets for the German market. The tablets are small, white and smooth, designed to be swallowed with water without a bitter taste.
Sanofi highlights that Thomapyrin should not be taken on an empty stomach, and the product information advises taking the tablets with a glass of water, preferably after a meal. That practical guidance matters for people who reach for the medicine at the first sign of a workday headache.
Who should and should not use it
According to the official German summary of product characteristics, Thomapyrin is intended for adults and adolescents over 12 years, subject to weight-related dosing for younger users. Children under 12 years are generally excluded due to the acetylsalicylic acid content and associated risk of Reye’s syndrome.
Patients with known hypersensitivity to salicylates, severe liver or kidney impairment, bleeding disorders or stomach ulcers are advised not to use Thomapyrin. The presence of caffeine also means it is unsuitable late at night for people sensitive to stimulants or with sleep problems.
Regulatory status and brand ownership
Thomapyrin is a registered over-the-counter medicine in Germany, marketed by Sanofi under its consumer healthcare division following the company’s acquisition and integration of various local brands. The product is listed in the German medicinal products registry with its specific approval number and dosage details.
On public regulatory portals, Thomapyrin’s marketing authorisation holder is shown as a Sanofi entity operating in Germany, under the umbrella of the French parent Sanofi S.A. headquartered in Paris. That structure means the brand contributes to Sanofi’s global consumer health revenues, alongside allergy, gastrointestinal and cold remedies.
Market positioning and competition
In German pharmacies and drugstores, Thomapyrin competes with ibuprofen and paracetamol generics as well as branded combination painkillers. Yet the triple combination of acetylsalicylic acid, paracetamol and caffeine gives it a distinct niche for tension and migraine headaches where rapid onset is valued.
Market reports on German consumer health note that pain relief remains one of the largest OTC segments by value, with headache tablets a staple purchase. Thomapyrin’s long presence and brand recognition make it a stable contributor rather than a new growth story.
Voices inside Sanofi and product strategy
In public statements, Sanofi CEO Paul Hudson has emphasised consumer healthcare as a pillar that provides steady cash flow next to innovative medicines and vaccines. Brands like Thomapyrin fit into that narrative as reliable OTC lines that demand ongoing marketing but limited R&D compared with new biologics.
German brand managers, such as the local consumer healthcare lead mentioned in trade interviews, focus more on dosage refinement, packaging updates and awareness campaigns than on changing the core formula. The product’s job is simple: keep people functioning through the day when headaches strike.
Pricing and availability in Germany
Price comparison portals show Thomapyrin Classic 20-tablet packs typically retailing between 6 and 9 euros in German online pharmacies, depending on discounts and shipping. Larger 50-tablet packs are more cost-effective per tablet but demand a higher upfront spend.
The medicine is widely available through pharmacies, online pharmacy platforms and some drugstore chains, though local rules often require that sales go through a pharmacist. Sanofi’s own site lists Thomapyrin as a standard OTC product with no prescription requirement for eligible age groups.
Risk information and patient guidance
Thomapyrin’s patient leaflet stresses that users must observe maximum daily doses and avoid combining the tablets with other paracetamol or acetylsalicylic acid products to prevent overdose. A warning about alcohol consumption underlines the increased risk of liver damage when paracetamol is involved.
The leaflet also points out possible side effects from stomach irritation to allergic reactions and insomnia due to caffeine. Users are advised to seek medical help if headaches persist for more than three days or recur frequently, as that can signal underlying conditions.
Investor angle: consumer health as a steady engine
For investors looking at Sanofi S.A., Thomapyrin is not the product grabbing headlines like a new cancer drug. Instead, it sits in the background as part of a broad OTC portfolio that supports recurring revenue and brand visibility in Germany.
On Euronext Paris, the Sanofi S.A. share (ISIN FR0000120578) reflects the performance of the entire group; sales of consumer painkillers such as Thomapyrin form a modest but steady contribution to that overall picture.
Thomapyrin key facts
- Product: Thomapyrin (Classic / Intensiv headache tablets)
- Manufacturer: Sanofi S.A.
- Category: Lifestyle / consumer OTC pain relief
- Market launch: Thomapyrin has been present in the German market for several decades; the current Classic and Intensiv variants reflect updated formulations and modern packaging, while the core triple-combination concept is long established.
- MSRP / Price: Around 6-9 EUR for a 20-tablet pack in German online pharmacies, depending on retailer and discount campaigns.
- Availability: Over-the-counter in German pharmacies, online pharmacies and some drugstores, with no prescription required for adults and adolescents over 12 years.
- Target group: Adults and adolescents suffering from mild to moderate headaches and stronger tension headaches, who need rapid relief without visiting a doctor immediately.
- Highlight / USP: Triple combination of acetylsalicylic acid, paracetamol and caffeine designed to provide faster and more effective headache relief than single-substance pain tablets in many everyday cases.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
